Amarin up 8% premarket on guidance boost

Citing increased demand for Vascepa (icosapent ethyl), Amarin (NASDAQ:AMRN) has raised its 2019 revenue guidance to $380M – 420M from $350M.

Q2 sales should be $97M – 101M while H1’s tally should be $170M – 174M.

It also plans to double the size of its U.S. salesforce. Recruiting is underway.

The FDA’s action date for its review of the company’s supplemental marketing application for a CV benefit claim for Vascepa is September 28.

Shares are up 8% premarket on light volume.

https://seekingalpha.com/news/3475189-amarin-8-percent-premarket-guidance-boost